We are delivering – Snapshot four

We are delivering: Research quality and quantity

  • Our output of around 800 scientific papers published in 2016 was the highest ever and has more than doubled in the past 10 years (to more than two papers per day).
  • There was a 10-fold increase in citations of our papers by researchers worldwide in the past 10 years (indicating the quality of our papers as judged by other researchers).
  • Average h-Index (an integrated measure of quality and quantity of a scientist’s output) of our Faculty is 42 (considered to be outstanding).
  • 28 of our researchers have had a publication that has been cited more than 1,000 times.

We are delivering: Research that is translated

  • There are 17 ongoing clinical trials based on our work and led by QIMR Berghofer researchers (in all four programs Cancer, Infectious Diseases, Mental health and Chronic Disorders).
  • Our researchers were involved in 35 third-party-sponsored ongoing clinical trials.
  • 47% of our research projects have moved forward from the discovery phase closer to translation.
  • We wholly own the clinical trials company, Q-Pharm.

We are delivering: Economic value

We are delivering: Star researchers

We are delivering: Directly to the community

  • We hosted over 1,000 high school students in our Education laboratory.
  • We presented to more than 1,000 students throughout Queensland as part of our regional outreach program.
  • We provided tours of the Institute and talks to almost 4,000 people.
  • We were active participants in the World Science Festival and the Guinness World Records largest ever practical science lesson.

Thanks to support from our donors and Queensland Health. As you can see, WE ARE DELIVERING.

QIMR Berghofer Medical Research Institute

Advertisements

We are delivering – Snap shot three

WE ARE DELIVERING: relevant discovery research

Our scientists:

  • Presented a paper on ‘The economics of skin cancer prevention’ to the World Health Organization.
  • Developed a mouse model to study Zika virus.
  • Described the genetic differences between those that have Barrett’s oesophageus and develop oesophageal cancer and those that don’t get the cancer.
  • Published information on genes associated with the risk of endometrial cancer.
  • Provided the first description of the anti-metastatic (prevention of secondaries) potential of the cancer immunotherapy we have developed.

WE ARE DELIVERING: research with practical consequences for the community

  • We developed and launched a personal skin cancer risk prediction tool for doctors and patients which can be delivered over the web.
    > Try the skin cancer risk prediction tool
  • We showed that melanoma rates in Australia are declining (a world first). Our recommendations for many years have been followed and are effective.
  • We have entered into an agreement to license technology that will help clinicians define the best treatment for pre-term babies who often have reduced oxygen levels in their blood.
  • Our Aboriginal and Torres Strait Islander Health Research program provides lectures in Cairns, Toowoomba and Rockhampton, with more locations planned for later this year. To date more than 1,200 students have been introduced to science and scientists from the Institute, and this number is growing annually.

WE ARE DELIVERING: progressive policies

  • We have introduced a novel ‘Entrepreneurs’ Leave of Absence’ policy to remove barriers for those that wish to take a temporary step away from the Institute and into a biotechnology company.
  • To help retain female researchers after maternity, we now provide financial support to allow them to balance their family/work demands, for instance by hiring a babysitter. We have a very high proportion of women in lead research positions (35%) and 53% of new faculty appointments in the last 5 years were women, but we want them and us to do better.

WE ARE DELIVERING: new ways of promoting commercialising research

  • We have established The SEED Box® (Scientific Exploitation and Entrepreneurial Development) to nurture and mature promising commercial projects.
  • CSL have joined us to identify, manage and support our Proof of Concept proposals.

Thanks to support from our donors and Queensland Health. As you can see, WE ARE DELIVERING.

QIMR Berghofer Medical Research Institute

We are delivering – Snap shot two

WE ARE DELIVERING: Quality Research

  • Three of our researchers are in the world’s top 1% Cited Authors in 2015
  • We received two Research Excellence Awards from the NHMRC
  • The World Congress of Psychiatrics selected one of our researchers for their Young Investigator Award 2015
  • 27 of our researchers have had a research paper that has been cited more than 1000 times

WE ARE DELIVERING: Relevant Research

  • 70 per cent of our teams have direct collaborations with clinicians
  • 50 per cent of our research is in Disease Oriented Discovery and 50 per cent is further along the path to translation
  • We recently collected the first brain images from the Herston Imaging Research Facility (established in collaboration with UQ, QUT and Metro North HSS)

WE ARE DELIVERING: Competitive Research

  • We were ranked second of all institutes and universities in Queensland and second in Australia for research funds awarded to institutes by the NHMRC to medical research
  • We provided four of the 10 named investigators from Queensland on the successful application by the Australian Genome Health Alliance

WE ARE DELIVERING: Translated Research

  • We published an extensive series of papers that showed how lifestyle choices are responsible for 37,000 new cases of cancer in Australia every year
  • We signed a very significant agreement with Atara Bio-therapeutics to deliver more immunotherapy solutions for a range of diseases. This follows an earlier major agreement with Bristol Myers Squibb for the application of other forms of immunotherapy
  • We launched a new immunotherapy trial for the treatment of glioblastomas (brain cancer)

Thanks to support from our donors and Queensland Health. As you can see, WE ARE DELIVERING

QIMRBerghofer_HLOGO_2COL_RGB

We are delivering – Snap shot one

There is always a balance to be reached between boasting about achievements and hiding a candle under a bushel.  QIMR Berghofer Medical Research Institute tries to get its messages out through the media.  There are frequent press releases and some of these get amplified.  However I don’t think we have really managed to do ourselves justice in showing just how great this Institute is.

So to step out of character 🙂 I thought I should launch a new occasional message from the Institute which I am calling We are delivering.  The first of these which highlights aspects of our work is below. It covers some aspects that were highlighted last month.  When you read it you will see that QIMR Berghofer really is a world-leading Institute, fulfilling many of the diverse tasks that you would expect when all those that are in the Institute are committed to having an impact on society through the research which we perform.  This is what we are doing:

QIMRBerghofer_HLOGO_2COL_RGB

WE ARE DELIVERING—Quality research

  • We published 506 peer reviewed  papers last year. That corresponds to two per working day. This is more than the papers published by any other well-known Medical Research Institute in Australia
  • Our papers are important for researchers world-wide. They were cited
    36 000 times in the last five years. This is more than the citations of  publications by any other Medical  Research  Institute in Australia.

WE ARE DELIVERING—Relevant research

  • A recent report from the Times Higher Education shows that we are ranked 7th in the world for citations used  in patent disclosures. No other Australian university or institute made this list of the 15 top providers of information that led to the patent.

WE ARE DELIVERING—Competitive research

  • We were awarded three of the nine EU-Australia research grants, and are the only Queensland institute to be successful
  • In a national  peer reviewed competition, we were  one of five recipients of a special grant ($6.4 million) to extend our work on dementia. There were no other successful Queensland applicants.

WE ARE DELIVERING—Translated research

  • We announced a very major collaboration agreement with Bristol-Myers Squibb (BMS) a world leader in Immuno-oncology. Immunotherapy is the fastest growing and most promising new approach to cancer treatment and we are recognised as world leaders
  • Research from our laboratories forms the basis for 27 clinical trials that are currently ongoing and we are participating in 23 other external trials
  • We announced, in collaboration with the University of Hong Kong, the start of a phase II clinical trial for the treatment of a specific head and neck  cancer that is prevalent in South East Asia. This is fully funded by donations from Hong Kong.

Thanks to support from our donors and Queensland Health. As you can see,
WE ARE DELIVERING.